At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02396 B&K CORP-B
Trading 01-12 13:19:27
13.060
+0.680
+5.49%
High13.650
Low12.010
Vol425.00K
Open12.380
D1 Closing12.380
Amplitude13.25%
Mkt Cap1.54B
Tradable Cap1.08B
Total Shares117.66M
T/O5.51M
T/O Rate0.51%
Tradable Shares83.02M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Hong Kong Stocks Movement | B&K CORP-B (02396) Plunges Over 12% in Morning Session to Record Low, Now Halved from IPO Price
HKEX Announcement Highlights | China Shenhua to Acquire Assets from Parent for ~¥133.6B and Raise Up to ¥20B; B&K Corp-B, Nanhua Futures Among 4 New Listings Tomorrow
Established in 2012, we are a biopharmaceutical company headquartered in China, dedicated to developing therapeutics, focusing on developing protein drugs for indications with medical needs and market opportunities. Our main focus is to discover, develop, and commercialize wound healing therapies, which are currently PDGF drugs. As of the last practical date, our pipeline contains ten candidate products, seven of which are PDGF drug candidates, including two core products, Pro-101-1 for treating burns and Pro-101-2 for treating sugar feet, which are rhPDGF-bB drugs.